Stay updated on Pembrolizumab in HCC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HCC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-25T19:06:54.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-11T07:27:07.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-04T02:45:30.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T19:23:25.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    The type of intervention has been updated from version v2.13.3 to v2.14.0.
    Difference
    0.3%
    Check dated 2025-01-13T11:36:08.000Z thumbnail image
  9. Check
    97 days ago
    Change Detected
    Summary
    The website has been updated from version 2.13.2 to 2.13.3.
    Difference
    0.1%
    Check dated 2024-12-15T18:59:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HCC Clinical Trial page.